Tags

Type your tag names separated by a space and hit enter

[Human papillomavirus prophylactic vaccines: stakes and perspectives].
Gynecol Obstet Fertil 2006 Jul-Aug; 34(7-8):647-55GO

Abstract

Human Papillomavirus (HPV) infection is established as the necessary cause of cervical precancers and cancers. To date, more than 120 genotypes are known, but only high risk oncogen genotypes could induce a cancer. HPV 16 and 18 are implied in nearly 70% of cervical cancer around the world. Although some persistent HPV infections progress to cervical cancer, host immunity is generally able to clear most HPV infections providing an opportunity for cervical cancer prevention through vaccination. Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are currently on human clinical trials: one targeting cervical cancer with a bivalent VLP L1 vaccine containing the two genotypes most frequently involved in cervical cancer (type 16 and 18) and the other, protecting against warts as well as cervical cancer, with a quadrivalent HPV VLP L1 vaccine containing genotypes 6, 11, 16 and 18. The first clinical trials revealed the satisfactory tolerance and excellent immunogenicity of these vaccines inducing high serum antibody titers with minimal side effects. After more than three years, both clinical trials on women 15 to 25 years old have shown that vaccines are able to type specifically protect against nearly 90% of infection and all cervical intra-epithelial neoplasia. The vaccinal strategy defined to date targets preadolescents and adolescent young females (11-13 years) before the first sexual course but some questions are still not resolved concerning the prescriber, the actors of the vaccination and the duration of the protection. Nevertheless cervical cancer screening should be carried on for many years, even if a large vaccinal strategy is decided. Such a vaccine would save lives and reduce the need for costly medical procedures and the psychological stress induced by this cancer.

Authors+Show Affiliations

Laboratoire de bactériologie-virologie-hygiène, CHRU Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France. sebastien.hantz@unilim.frNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

16807045

Citation

Hantz, S, et al. "[Human Papillomavirus Prophylactic Vaccines: Stakes and Perspectives]." Gynecologie, Obstetrique & Fertilite, vol. 34, no. 7-8, 2006, pp. 647-55.
Hantz S, Alain S, Denis F. [Human papillomavirus prophylactic vaccines: stakes and perspectives]. Gynecol Obstet Fertil. 2006;34(7-8):647-55.
Hantz, S., Alain, S., & Denis, F. (2006). [Human papillomavirus prophylactic vaccines: stakes and perspectives]. Gynecologie, Obstetrique & Fertilite, 34(7-8), pp. 647-55.
Hantz S, Alain S, Denis F. [Human Papillomavirus Prophylactic Vaccines: Stakes and Perspectives]. Gynecol Obstet Fertil. 2006;34(7-8):647-55. PubMed PMID: 16807045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Human papillomavirus prophylactic vaccines: stakes and perspectives]. AU - Hantz,S, AU - Alain,S, AU - Denis,F, Y1 - 2006/06/27/ PY - 2006/03/31/received PY - 2006/05/19/accepted PY - 2006/6/30/pubmed PY - 2006/10/13/medline PY - 2006/6/30/entrez SP - 647 EP - 55 JF - Gynecologie, obstetrique & fertilite JO - Gynecol Obstet Fertil VL - 34 IS - 7-8 N2 - Human Papillomavirus (HPV) infection is established as the necessary cause of cervical precancers and cancers. To date, more than 120 genotypes are known, but only high risk oncogen genotypes could induce a cancer. HPV 16 and 18 are implied in nearly 70% of cervical cancer around the world. Although some persistent HPV infections progress to cervical cancer, host immunity is generally able to clear most HPV infections providing an opportunity for cervical cancer prevention through vaccination. Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are currently on human clinical trials: one targeting cervical cancer with a bivalent VLP L1 vaccine containing the two genotypes most frequently involved in cervical cancer (type 16 and 18) and the other, protecting against warts as well as cervical cancer, with a quadrivalent HPV VLP L1 vaccine containing genotypes 6, 11, 16 and 18. The first clinical trials revealed the satisfactory tolerance and excellent immunogenicity of these vaccines inducing high serum antibody titers with minimal side effects. After more than three years, both clinical trials on women 15 to 25 years old have shown that vaccines are able to type specifically protect against nearly 90% of infection and all cervical intra-epithelial neoplasia. The vaccinal strategy defined to date targets preadolescents and adolescent young females (11-13 years) before the first sexual course but some questions are still not resolved concerning the prescriber, the actors of the vaccination and the duration of the protection. Nevertheless cervical cancer screening should be carried on for many years, even if a large vaccinal strategy is decided. Such a vaccine would save lives and reduce the need for costly medical procedures and the psychological stress induced by this cancer. SN - 1297-9589 UR - https://www.unboundmedicine.com/medline/citation/16807045/[Human_papillomavirus_prophylactic_vaccines:_stakes_and_perspectives]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1297-9589(06)00187-1 DB - PRIME DP - Unbound Medicine ER -